BI 1569912 / Boehringer Ingelheim  >>  Phase 1
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
BI 1569912 / Boehringer Ingelheim
NCT04445090: A Study in Healthy Men to Test How Well Different Doses of BI 1569912 Are Tolerated and How Food Influences the Amount of BI 1569912 in the Blood

Terminated
1
68
Europe
BI 1569912, Placebo
Boehringer Ingelheim
Healthy
09/21
09/21
NCT04937829: A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication

Completed
1
59
US
BI 1569912, Placebo
Boehringer Ingelheim
Depressive Disorder, Major
11/23
11/23
NCT04958252: A Study in Healthy Japanese Men to Test How Different Doses of BI 1569912 Are Taken up by the Body and How Well They Are Tolerated

Active, not recruiting
1
56
Japan
BI 1569912, Placebo
Boehringer Ingelheim
Healthy
10/23
10/23
NCT04978506: A Study in Healthy Men to Test How Well Different Doses of BI 1569912 Are Tolerated

Active, not recruiting
1
76
Europe
BI 1569912, Placebo
Boehringer Ingelheim
Healthy
07/24
07/24
NCT06367153: A Study in Healthy Men and Women to Test Whether BI 1569912 Influences the Amount of Repaglinide, Midazolam and Bupropion in the Blood

Active, not recruiting
1
18
Europe
BI 1569912, repaglinide, midazolam, bupropion
Boehringer Ingelheim
Healthy
08/24
08/24

Download Options